The 'Metabolic Divide' has widened into a chasm this week as Gilead Sciences continues to blockade access to lenacapavir, a breakthrough twice-yearly injectable HIV prevention drug. Despite calls from Doctors Without Borders and global health advocates, the pharmaceutical giant has refused to provide a national access plan for low-income countries, effectively gating biological survival behind a corporate paywall. While Gilead touts non-profit deals with the Global Fund, experts argue these measures are insufficient to curb the epidemic in resource-limited nations. This enclosure of the body is being compounded by the Trump administration’s hollowing out of PEPFAR. Budget czar Russell Vought has moved to slash programs that have historically been the only line of defense for millions of HIV patients. Activists interrupted congressional hearings this week with the cry 'Vought cuts kill people,' highlighting the deliberate starvation of public health infrastructure. This is the logical endpoint of the 'Subscription Body' model: health is no longer a human right but a recurring revenue stream. While the Global North accesses premium therapies through gated pharmacies, the Global South is left to wait for crumbs of appropriated funding that may never arrive. The commodification of survival is the ultimate form of 'Imperial Triage,' where the lives of the poor are traded for the quarterly dividends of biotech monopolies.